Piramal Healthcare UK Ltd., a subsidiary of the Indian Piramal group, is spending £2 million to expand its manufacturing base for antibody drug conjugates at Grangemouth, Scotland. The company said the new investment, which is receiving a grant of £200,000 as part of the UK’s Regional Selective Assistance funding, will yield additional revenue of £3-5 million over five years and create up to 20 new high-skilled jobs.

Under the recent launch of the industry-led life and chemical sciences manufacturing strategy, Scotland sees itself positioned as a globally competitive base for sustainable high-value manufacturing. Piramal Healthcare is a key element to the Scottish antibody drug conjugate (ADC) hub.

Mark Wright, site lead, Piramal Healthcare, said the company has been growing its operations at Grangemouth since 2005 and currently employs around 140 people in predominantly highly skilled positions.

Wright said the facility will be scaled up over the next five years to maintain its position as a global leader in the production of antibody drug conjugates.